Redona Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 9

Redona Therapeutics General Information

Description

Developer of RNA drugs designed to treat cancer and other human diseases. The company's drugs are developed by researching short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay, and developing small molecules that can modulate levels of miRNAs by targeting proteins that interact with these, enabling health advisors to target miRNAs that are directly involved in cancer initiation, progression, and metastasis.

Contact Information

Formerly Known As
Twentyeight-Seven
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 490 Arsenal Way
  • Suite 100B
  • Watertown, MA 02472
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 490 Arsenal Way
  • Suite 100B
  • Watertown, MA 02472
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Redona Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private Completed Clinical Trials - General
5. Later Stage VC 31-Jul-2023 Completed Clinical Trials - General
4. Later Stage VC (Series A) 16-Jun-2022 Completed Clinical Trials - General
3. Early Stage VC (Series A) 05-Apr-2016 Completed Startup
2. University Spin-Out 01-Jan-2016 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Redona Therapeutics’s complete valuation and funding history, request access »

Redona Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Redona Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Redona Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of RNA drugs designed to treat cancer and other human diseases. The company's drugs are developed by researchi
Drug Discovery
Watertown, MA
22 As of 2023

Ramat-Gan, Israel
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Redona Therapeutics Competitors (100)

One of Redona Therapeutics’s 100 competitors is Silexion Therapeutics, a Formerly VC-backed company based in Ramat-Gan, Israel.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Silexion Therapeutics Formerly VC-backed Ramat-Gan, Israel
WaVe Life Sciences Formerly VC-backed Cambridge, MA
Sirnaomics Formerly VC-backed Gaithersburg, MD
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Atalanta Therapeutics Venture Capital-Backed Boston, MA
You’re viewing 5 of 100 competitors. Get the full list »

Redona Therapeutics Patents

Redona Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023196629-A1 Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer Inactive 07-Apr-2022
AU-2022374702-A1 Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer Pending 25-Oct-2021
CA-3236083-A1 Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer Pending 25-Oct-2021
EP-4423070-A1 Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer Pending 25-Oct-2021
US-20260159486-A1 Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer Pending 25-Oct-2021 C07D239/94
To view Redona Therapeutics’s complete patent history, request access »

Redona Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Redona Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Johnson & Johnson JJDC Corporate Venture Capital Minority
Longwood Fund Management Venture Capital Minority
Novartis Venture Fund Corporate Venture Capital Minority
Osage University Partners Venture Capital Minority
Sofinnova Partners Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Redona Therapeutics FAQs

  • When was Redona Therapeutics founded?

    Redona Therapeutics was founded in 2016.

  • Where is Redona Therapeutics headquartered?

    Redona Therapeutics is headquartered in Watertown, MA.

  • What is the size of Redona Therapeutics?

    Redona Therapeutics has 22 total employees.

  • What industry is Redona Therapeutics in?

    Redona Therapeutics’s primary industry is Drug Discovery.

  • Is Redona Therapeutics a private or public company?

    Redona Therapeutics is a Private company.

  • What is Redona Therapeutics’s current revenue?

    The current revenue for Redona Therapeutics is .

  • How much funding has Redona Therapeutics raised over time?

    Redona Therapeutics has raised $89.7M.

  • Who are Redona Therapeutics’s investors?

    Johnson & Johnson JJDC, Longwood Fund Management, Novartis Venture Fund, Osage University Partners, and Sofinnova Partners are 5 of 9 investors who have invested in Redona Therapeutics.

  • Who are Redona Therapeutics’s competitors?

    Silexion Therapeutics, WaVe Life Sciences, Sirnaomics, Intellia Therapeutics, and Atalanta Therapeutics are some of the 100 competitors of Redona Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process